{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:31:45Z","timestamp":1788777105092,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003711","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["104-2314-B-038-037"],"award-info":[{"award-number":["104-2314-B-038-037"]}],"id":[{"id":"10.13039\/501100003711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003711","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["105-2314-B-038-043-MY3"],"award-info":[{"award-number":["105-2314-B-038-043-MY3"]}],"id":[{"id":"10.13039\/501100003711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wan Fang Hospital","award":["105TMU-WFH-07"],"award-info":[{"award-number":["105TMU-WFH-07"]}]},{"name":"Wan Fang Hospital","award":["105-wf-eva-04"],"award-info":[{"award-number":["105-wf-eva-04"]}]}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.schres.2017.07.022","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T13:01:32Z","timestamp":1500123692000},"page":"139-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Application of plasma levels of olanzapine and N -desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia"],"prefix":"10.1016","volume":"193","author":[{"given":"Mong-Liang","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ting","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.schres.2017.07.022_bb0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.schres.2014.09.020","article-title":"Use of very-high-dose olanzapine in treatment-resistant schizophrenia","volume":"159","author":"Batail","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1\u20132","key":"10.1016\/j.schres.2017.07.022_bb0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.schres.2017.07.022_bb0015","article-title":"Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis","author":"Bioque","year":"2017","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2017.07.022_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.schres.2017.07.022_bb0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"Citrome","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2017.07.022_bb0030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003495-199753020-00007","article-title":"Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses","volume":"53","author":"Fulton","year":"1997","journal-title":"Drugs"},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.07.022_bb0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","article-title":"Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model","volume":"131","author":"Hahn","year":"2011","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2017.07.022_bb0040","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.07.022_bb0045","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","article-title":"Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses","volume":"2","author":"Henderson","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2017.07.022_bb0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.schres.2017.07.022_bb0055","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1600-0447.2009.01401.x","article-title":"Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan","volume":"120","author":"Huang","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"8","key":"10.1016\/j.schres.2017.07.022_bb0060","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0929-6646(09)60161-3","article-title":"Prevalence of obesity and metabolic syndrome in Taiwan","volume":"105","author":"Hwang","year":"2006","journal-title":"J. Formos. Med. Assoc."},{"issue":"1","key":"10.1016\/j.schres.2017.07.022_bb0065","first-page":"81","article-title":"Disposition and biotransformation of the antipsychotic agent olanzapine in humans","volume":"25","author":"Kassahun","year":"1997","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.schres.2017.07.022_bb0070","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/hup.781","article-title":"Plasma concentrations of high-dose olanzapine in a double-blind crossover study","volume":"21","author":"Kelly","year":"2006","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.schres.2017.07.022_bb0075","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","volume":"3","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.schres.2017.07.022_bb0080","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.07.022_bb0085","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.schres.2013.04.002","article-title":"Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature","volume":"147","author":"Lopez","year":"2013","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2017.07.022_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065719","article-title":"Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters","volume":"8","author":"Lu","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.schres.2017.07.022_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148539","article-title":"Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor clinical efficacy in patients with schizophrenia","volume":"11","author":"Lu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2017.07.022_bb0100","first-page":"749","article-title":"Olanzapine approved for the acute treatment of schizophrenia or manic\/mixed episodes associated with bipolar I disorder in adolescent patients","volume":"6","author":"Maloney","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.schres.2017.07.022_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.07.022_bb0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"issue":"2","key":"10.1016\/j.schres.2017.07.022_bb0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-003-1529-4","article-title":"Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses","volume":"170","author":"Melkersson","year":"2003","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.schres.2017.07.022_bb0120","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003495-200464070-00003","article-title":"Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications","volume":"64","author":"Melkersson","year":"2004","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.schres.2017.07.022_bb0125","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4088\/JCP.v61n1006","article-title":"Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses","volume":"61","author":"Melkersson","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.07.022_bb0130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2017.07.022_bb0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial","volume":"21","author":"Perry","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2017.07.022_bb0140","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.jcp.0000162800.64378.82","article-title":"The association of weight gain and olanzapine plasma concentrations","volume":"25","author":"Perry","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.07.022_bb0145","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MED.0b013e32833de61c","article-title":"Metabolic syndrome with the atypical antipsychotics","volume":"17","author":"Pramyothin","year":"2010","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"1","key":"10.1016\/j.schres.2017.07.022_bb0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2014pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.schres.2017.07.022_bb0155","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1520\/JFS14697J","article-title":"Olanzapine concentrations in clinical serum and postmortem blood specimens\u2014when does therapeutic become toxic?","volume":"45","author":"Robertson","year":"2000","journal-title":"J. Forensic Sci."},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.07.022_bb0160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2017.07.022_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiat."},{"issue":"7","key":"10.1016\/j.schres.2017.07.022_bb0170","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.07.022_bb0175","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/diacare.27.5.1182","article-title":"Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?","volume":"27","author":"Tan","year":"2004","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.schres.2017.07.022_bb0180","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417304231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417304231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T01:59:23Z","timestamp":1535594363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417304231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":36,"alternative-id":["S0920996417304231"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.07.022","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}